Walleye Capital
CGEM icon

Walleye Capital’s Cullinan Oncology CGEM Stock Holding History

Walleye Capital’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-56,736
Closed -$336K – 4615
2025
Q3 		$336K Buy
56,736
+21,537
+61% +$158K ﹤0.01% 2916
2025
Q2 		$265K Buy
35,199
+13,199
+60% +$106K ﹤0.01% 3157
2025
Q1 		$167K Sell
22,000
-134,497
-86% -$1.29M ﹤0.01% 3396
2024
Q4 		$1.91M Sell
156,497
-171,920
-52% -$2.47M ﹤0.01% 1820
2024
Q3 		$5.5M Buy
328,417
+235,548
+254% +$4.18M 0.01% 1110
2024
Q2 		$1.62M Buy
+92,869
New +$1.98M ﹤0.01% 2317

Other funds holding CGEM

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Walleye Capital's CGEM Position: Q4 2025 in Review

Walleye Capital sold out of Cullinan Oncology (CGEM) in Q4 2025, closing a stake of 56,736 shares — an estimated $336K sold.

Walleye Capital first reported a position in CGEM in Q2 2024 and held it in 6 quarters. The position peaked at $5.5M in Q3 2024. 153 funds tracked by Wall St. Rank hold CGEM as of Q4 2025.

  • Walleye Capital reported no remaining Cullinan Oncology position as of Q4 2025 after selling out during the quarter.
  • Walleye Capital sold 56,736 Cullinan Oncology shares in Q4 2025, an estimated $336K.
  • Walleye Capital first reported a position in Cullinan Oncology in Q2 2024 and held it in 6 quarters.
  • Walleye Capital's Cullinan Oncology position peaked at $5.5M in Q3 2024.
  • 153 funds tracked by Wall St. Rank held Cullinan Oncology as of Q4 2025.

Based on Walleye Capital's 13F filing for Q4 2025, filed 13 Feb 2026.